Results 241 to 250 of about 93,749 (369)

Granular Cell Tumor of the Pituitary Gland Associated with Diabetes Insipidus

open access: hybrid, 1980
Lawrence B. Schlachter   +2 more
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Are physiological oscillations physiological?

open access: yesThe Journal of Physiology, EarlyView., 2023
Abstract figure legend Mechanisms and functions of physiological oscillations. Abstract Despite widespread and striking examples of physiological oscillations, their functional role is often unclear. Even glycolysis, the paradigm example of oscillatory biochemistry, has seen questions about its oscillatory function.
Lingyun (Ivy) Xiong, Alan Garfinkel
wiley   +1 more source

Diagnosis of Tumors of the Pituitary Region by Two-plane CT Scans

open access: bronze, 1981
Minoru Murata   +5 more
openalex   +2 more sources

Dimerisation of the VIP receptor VIPR2 is essential to its binding VIP and Gαi proteins, and to its functions in breast cancer cells

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Several G protein‐coupled receptors (GPCRs) are known to homodimerise. Dimeric GPCRs may have different properties from their monomers, but the molecular basis and functional significance of GPCR dimerisation remain largely unknown.
Satoshi Asano   +6 more
wiley   +1 more source

Outcome of giant pituitary tumors requiring surgery. [PDF]

open access: yesFront Endocrinol (Lausanne), 2022
Gaillard S   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy